July 12, 2012, Parsippany, NJ, USA – The STA® – Rivaroxaban Calibrator and Controls are highly specific, automation-ready products for determining the rivaroxaban concentration in plasma when used in conjunction with the STA® - Liquid Anti-Xa assay. This method was shown to have favorable performance with respect to its linearity and coefficient of variation (CV) in a recent publication.1
June 29, 2012, Parsippany, NJ, USA – Diagnostica Stago, Inc. announces products to suit a variety of clinical research needs for factor VII (FVII). Factor VII is a zymogen that upon activation to its active form, factor VIIa (FVIIa) together with Tissue Factor (TF) comprises the first step in the extrinsic pathway of blood coagulation leading to thrombin formation and subsequent formation of the fibrin clot. Fibrin...
January 4, 2012, Parsippany, NJ, USA – Diagnostica Stago announces three new products to suit a variety of clinical research needs for procoagulant and total microparticle detection. Microparticles are tissue factor-bearing phospholipid vesicles that have often been the subject of clinical research studies into various conditions such as cancer, diabetes, sickle cell disorder, as well as parasitic and viral infectio...
July 1, 2011, Parsippany, NJ, USA – Diagnostica Stago, Inc. (DSI), recently finalized the acquisition of Thrombinoscope BV, based in Maastricht, The Netherlands. This company, researches, develops and markets thrombin generation (TG) systems through the use of the Calibrated Automated Thrombogram® (CAT) system. This system is available for research-only use – and should not be used for diagnostic purposes.
Diagnostica Stago, Inc., (DSI) is an industry leader in the science of hemostasis and thrombosis. Stago provides the total commitment of global resources and responsiveness, coupled with cutting edge technology and reliability. DSI is dedicated to continually developing and providing the very best hemostasis products, technical support, and services.
Our primary mission is to provide laboratory and healthcare professionals with reliable, powerful and innovative hemostasis diagnostic instruments and reagents. We consistently strive to improve methods for prevention, understanding, diagnostic, treatment and follow-up of coagulation-related disorders.
June 29 - July 4, 2013
July 28 - August 1, 2013
December 7 - 10, 2013
Did you know?
In 1953, Dr R. Langdell et al. proposed a plasma clotting test that could be used for assaying antihemophilic factor. They designated their one-stage test as "partial thromboplastin time".